<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002784</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064834</org_study_id>
    <secondary_id>IBCSG-15-95</secondary_id>
    <secondary_id>EU-96021</secondary_id>
    <nct_id>NCT00002784</nct_id>
  </id_info>
  <brief_title>High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer</brief_title>
  <acronym>15-95</acronym>
  <official_title>Randomized Trial of High-dose Epirubicin and Cyclophosphamide x 3 Supported by Peripheral Blood Progenitor Cells Versus Anthracycline and Cyclophosphamide x 4 Followed by Cyclophosphamide, Methotrexate, and 5-fluorouracil x 3 as Adjuvant Treatment for High Risk Operable Stage ii and Stage Iii Breast Cancer in Premenopausal and Young Postmenopausal (Less Than or Equal to 65 Yrs) Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It
      is not yet known if high-dose combination chemotherapy plus peripheral stem cell
      transplantation is more effective than standard combination chemotherapy for breast cancer.

      PURPOSE: Randomized phase III trial to compare high-dose combination chemotherapy plus
      peripheral stem cell transplantation with standard combination chemotherapy in treating women
      with stage II or stage III breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the survival, disease-free survival, and systemic disease-free
      survival of women with high-risk, operable stage II/III breast cancer treated with three
      courses of dose-intensive epirubicin/cyclophosphamide (EC) supported by granulocyte
      colony-stimulating factor (G-CSF) and G-CSF-mobilized peripheral blood stem cells vs.
      standard EC followed by cyclophosphamide/methotrexate/fluorouracil. II. Compare the toxicity,
      duration of quality-adjusted time without symptoms and toxicity, and quality of life
      associated with these two treatments. III. Evaluate the cost effectiveness of these two
      treatments.

      OUTLINE: This is a randomized study. Patients are stratified by estrogen receptor status and
      menopausal status. Within 6 weeks of surgery, patients in the first group receive epirubicin
      (preferred) or doxorubicin plus cyclophosphamide every 3 weeks for 4 courses followed by
      conventional cyclophosphamide, methotrexate, and fluorouracil (CMF) every 4 weeks for 3
      courses. Patients in the second group undergo stem cell mobilization and harvest with
      granulocyte colony-stimulating factor (G-CSF) followed within 10 weeks of surgery by
      high-dose chemotherapy with epirubicin and cyclophosphamide followed by peripheral blood stem
      cell rescue and G-CSF. All patients receive adjuvant tamoxifen, and patients who underwent
      lumpectomy prior to entry are required to receive adjuvant radiotherapy (radiotherapy is
      optional for patients who underwent mastectomy prior to entry). Patients are followed every 3
      months for 2 years, then q 6 months for 3 years, then yearly.

      PROJECTED ACCRUAL: 210 patients will be accrued over 4 years to provide 195 evaluable
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1996</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival.</measure>
    <time_frame>16 years after randomization.</time_frame>
    <description>Time from randomization to recurrence (including recurrence isolated to the breast), metastasis, appearance of a second primary tumor, or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>16 years after randomization.</time_frame>
    <description>Time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity.</measure>
    <time_frame>5 years after randomization.</time_frame>
    <description>Morbidity information was recorded using standard toxicity criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life.</measure>
    <time_frame>16 years after randomization.</time_frame>
    <description>Quality of life was assessed using standard International Breast Cancer Study Group instruments.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">344</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Standard chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EC/AC x 4 followed by CMF x 3 and tamoxifen to 5 years after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-intensive EC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose EC x 3 supported by peripheral blood progenitor cells and tamoxifen to 5 years after randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Filgrastim 10 mg/kg/d sc for 6 days after randomization.</description>
    <arm_group_label>Dose-intensive EC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CMF regimen</intervention_name>
    <description>Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.</description>
    <arm_group_label>Standard chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.</description>
    <arm_group_label>Standard chemotherapy</arm_group_label>
    <arm_group_label>Dose-intensive EC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.</description>
    <arm_group_label>Standard chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
    <description>Epirubicin 90 mg/m2 iv on day 1 of 21-day cycles of EC.</description>
    <arm_group_label>Standard chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.</description>
    <arm_group_label>Standard chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesna</intervention_name>
    <description>MESNA (7.2 gm/m2) on days 2 and 3 of 21-day cycles of dose-intensive EC.</description>
    <arm_group_label>Dose-intensive EC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.</description>
    <arm_group_label>Standard chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <description>Tamoxifen 20mg daily for 5 years or until relapse.</description>
    <arm_group_label>Standard chemotherapy</arm_group_label>
    <arm_group_label>Dose-intensive EC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Peripheral blood progenitor cells (PBPC) infusion on day 5 of each 21-day cycle of dose-intensive EC.</description>
    <arm_group_label>Dose-intensive EC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET electron therapy</intervention_name>
    <description>Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.</description>
    <arm_group_label>Standard chemotherapy</arm_group_label>
    <arm_group_label>Dose-intensive EC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET photon therapy</intervention_name>
    <description>radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.</description>
    <arm_group_label>Standard chemotherapy</arm_group_label>
    <arm_group_label>Dose-intensive EC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven breast carcinoma in one of the following
        categories: 10 or more involved axillary nodes 5 or more involved axillary nodes and
        either: Primary tumor estrogen receptor (ER)-negative (less than 10 femtomoles per
        milligram of cytosol protein) T3 tumor (regardless of ER status) Total mastectomy or
        breast-conserving procedure (lumpectomy or quadrantectomy) required within 6 weeks prior to
        randomization Tumor confined to breast and axillary nodes (T1a-c, T2, or T3, N1-2, M0 by
        the UICC staging system) The following conditions exclude entry: Satellite skin nodules
        distant from the primary tumor Supraclavicular node involvement Inoperable, matted axillary
        nodes Fixation of primary tumor to chest wall (excluding pectoralis major) Bilateral breast
        cancer (any mass in opposite breast unless biopsy-proven benign) Hot spots on bone
        scintigram (unless confirmed to be benign) Skeletal pain of unknown cause Hormone receptor
        status: ER status determination preferred, but not required

        PATIENT CHARACTERISTICS: Age: 16-65 Sex: Women only Menopausal status: Any status
        Performance status: ECOG 0-2 Hematopoietic: WBC at least 4,000 Platelets at least 100,000
        Hepatic: Bilirubin no greater than 1.1 mg/dL (20 micromoles/L) AST no greater than twice
        normal Renal: Creatinine no greater than 1.3 mg/dL (120 micromoles/L) Cardiovascular: Left
        ventricular ejection fraction greater than 50% by MUGA Other: No second malignancy except:
        Basal cell carcinoma Adequately treated carcinoma in situ of the cervix No significant
        nonmalignant disease that would preclude participation No psychiatric or addictive disorder
        that would compromise informed consent or participation No pregnant or nursing women
        Adequate contraception strongly advised for fertile women

        PRIOR CONCURRENT THERAPY: No prior therapy for breast cancer other than surgery (see
        Disease Characteristics)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell Basser, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Newcastle Mater Misericordiae Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>NSW 2310</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital, Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swiss Institute for Applied Cancer Research</name>
      <address>
        <city>Bern</city>
        <zip>CH-3008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana</name>
      <address>
        <city>Lugano</city>
        <zip>CH-6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - Saint Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008 Jun 20;26(18):3006-14. doi: 10.1200/JCO.2007.14.9336. Epub 2008 May 5.</citation>
    <PMID>18458044</PMID>
  </reference>
  <reference>
    <citation>Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thürlimann B, Mendiola C, Aebi S, Price KN, Pagani O, Simoncini E, Castiglione Gertsch M, Gelber RD, Coates AS, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol. 2007 Apr;18(4):701-8. Epub 2007 Jan 20.</citation>
    <PMID>17237474</PMID>
  </reference>
  <results_reference>
    <citation>Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS, Gelber RD, Green MD, Peccatori F, Cinieri S, Aebi S, Viale G, Price KN, Goldhirsch A; International Breast Cancer Study Group. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol. 2009 Aug;20(8):1344-51. doi: 10.1093/annonc/mdp024. Epub 2009 May 25.</citation>
    <PMID>19468030</PMID>
  </results_reference>
  <results_reference>
    <citation>International Breast Cancer Study Group, Basser RL, O'Neill A, Martinelli G, Green MD, Peccatori F, Cinieri S, Coates AS, Gelber RD, Aebi S, Castiglione-Gertsch M, Viale G, Price KN, Goldhirsch A. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol. 2006 Jan 20;24(3):370-8.</citation>
    <PMID>16421418</PMID>
  </results_reference>
  <results_reference>
    <citation>Basser RL, Abraham R, To LB, Fox RM, Green MD. Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer. Ann Oncol. 1999 Jan;10(1):53-8.</citation>
    <PMID>10076722</PMID>
  </results_reference>
  <results_reference>
    <citation>Basser RL, To LB, Collins JP, Begley CG, Keefe D, Cebon J, Bashford J, Durrant S, Szer J, Kotasek D, Juttner CA, Russell I, Maher DW, Olver I, Sheridan WP, Fox RM, Green MD. Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up. J Clin Oncol. 1999 Jan;17(1):82-92.</citation>
    <PMID>10458221</PMID>
  </results_reference>
  <results_reference>
    <citation>Basser RL, To LB, Begley CG, Juttner CA, Maher DW, Szer J, Cebon J, Collins JP, Russell I, Olver I, et al. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. Clin Cancer Res. 1995 Jul;1(7):715-21.</citation>
    <PMID>9816037</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2004</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

